Simultaneous phenotypic and genetic characterization of single circulating tumor cells from colon cancer patients

Histology and Histopathology

Volumn 28, Issue 11, 2013, Pages 1439-1450

  Campos, María ^a   Luque, Rafael ^b   Jiménez, Juan ^b   Martínez, Rafael ^b   Warleta, Fernando ^a   Sánchez Quesada, Cristina ^a   Delgado Rodríguez, Miguel ^a,c   Calvo, Alfonso ^d   Gaforio, José J ^a  

^a UNIVERSITY OF JAÉN   (Spain)

^b University Hospital of Jaen   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

CK+ CTCS; Colon cancer; ERBB2; FICTION; HER2

Indexed keywords

KERATIN;

ADENOCARCINOMA; ARTICLE; BLOOD; CANCER GRADING; CANCER STAGING; CELL SEPARATION; CHROMOSOME 17; COLON TUMOR; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; METHODOLOGY; PATHOLOGY; PHENOTYPE; PROTO ONCOGENE; TUMOR EMBOLISM;

ADENOCARCINOMA; CELL SEPARATION; CHROMOSOMES, HUMAN, PAIR 17; COLONIC NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATINS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PHENOTYPE;

EID: 84886295703     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Al-Kuraya K., Novotny H., Bavi P., Siraj A.K., Uddin S., Ezzat A., Sanea N.A., Al-Dayel F., Al-Mana H., Sheikh S.S., Mirlacher M., Tapia C., Simon R., Sauter G., Terracciano L. and Tornillo L. (2007). HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J. Clin. Pathol. 60, 768-772.
2. Camara O., Rengsberger M., Egbe A., Koch A., Gajda M., Hammer U., Jörke C., Rabenstein C., Untch M. and Pachmann K. (2007) The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann. Oncol. 18, 1484-1492.
3. Campos M., Prior C., Warleta F., Zudaire I., Ruiz-Mora J., Catena R., Calvo A. and Gaforio J.J. (2008). Phenotypic and genetic characterization of circulating tumor cells by combining immunomagnetic selection and FICTION techniques. J. Histochem. Cytochem. 56, 667-675.
4. Cao S., Li Y., Li J., Li C.F., Zhang W., Yang Z.Q. and Meng S.D. (2010). Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer. Oncol. Rep. 23, 423-428.
5. Choi J.H., Han H.S., Lee H.C., Lee O.J., Kim J.T., Lim S.N., Lee K.H. and Kim S.T. (2011). Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia. Onkologie 34, 621-624.
6. Cohen S.J., Alpaugh R.K., Gross S., O'Hara S.M., Smirnov D.A., Terstappen L.W., Allard W.J., Bilbee M., Cheng J.D., Hoffman J.P., Lewis N.L., Pellegrino A., Rogatko A., Sigurdson E., Wang H., Watson J.C., Weiner L.M. and Meropol N.J. (2006). Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer. 6, 125-132.
7. Cohen S.J., Punt C.J.A., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W. and Meropol N.J. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213-3221.
8. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M.A., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W. and Meropol N.J. (2009). Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 20, 1223-1229.
9. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W.M.M. and Hayes D.F. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791.
10. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., Doyle G.V., Matera J., Allard W.J., Miller M.C., Fritsche H.A., Hortobagyi G.N. and Terstappen L.W. (2005). Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23, 1420-1430.
11. Dursun A., Poyraz A., Süer O., Sezer C. and Akyol G. (2001). Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol. Oncol. Res. 7, 24-27.
12. Facchini L.M. and Penn L.Z. (1998). The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J. 12, 633-651.
13. Fehm T., Sagalowsky A., Clifford E., Beitsch P., Saboorian H., Euhus D., Meng S., Morrison L., Tucker T., Lane N., Ghadimi B.M., Heselmeyer-Haddad K., Ried T., Rao C. and Uhr J. (2002). Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin. Cancer Res. 8, 2073-2084.
14. Fehm T., Becker S., Duerr-Stoerzer S., Sotlar K., Mueller V., Wallwiener D., Lane N., Solomayer E. and Uhr J. (2007). Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 9, R74.
15. Fehm T., Müller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., Lattrich C., Löhberg C.R., Solomayer E., Rack B., Riethdorf S., Klein C., Schindlbeck C., Brocker K., Kasimir-Bauer S., Wallwiener D. and Pantel K. (2010). HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 124, 403-412.
16. Gaforio J.J., Serrano M.J., Sánchez-Rovira P., Antonio Sirvent A., Delgado-Rodriguez M., Campos M., de la Torre N., Algarra I., Dueñas R. and Lozano A. (2003). Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int. J. Cancer. 107, 984-990.
17. Javle M. and Hsueh C.T. (2010). Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J. Hematol. Oncol. 3, 11.
18. Jemal A., Bray F., Center M.M., Ferlay J., Ward E. and Forman D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
19. Kavanagh D.O., Chambers G., O'Grady L., Barry K.M., Waldron R.P., Bennani F., Eustace P.W. and Tobbiah I. (2009). Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?. BMC Cancer. 9,1.
20. Kelly R.J., Carter C. and Giaccone G. (2010). Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitorresistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J. Clin. Oncol. 28, e507-510.
21. Koch M., Kienle P., Kastrati D., Antolovic D., Schmidt J., Herfarth C., von Knebel Doeberitz M. and Weitz J. (2006). Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int. J. Cancer 118, 3072-3077.
22. Kuwada S.K., Scaife C.L., Kuang J., Li X., Wong R.F., Florell S.R., Coffey R.J. Jr and Gray P. (2004). Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int. J. Cancer 109, 291-301.
23. Langer C.J., Stephenson P., Thor A., Vangel M. and Johnson D.H. (2004). Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J. Clin. Oncol. 22, 1180-1187.
24. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., Mayer R.J., Macdonald J.S., Catalano P.J. and Haller D.G. (2003). Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J. Clin. Oncol. 21, 2912-2919.
25. Madarnas Y., Trudeau M., Franek J.A., McCready D., Pritchard K.I. and Messersmith H. (2008). Adjuvant/neoadjuvant trastuzumab therapy in women with HER2/neu-overexpressing breast cancer: A systematic review. Cancer Treat. Rev. 34, 539-557.
26. Maestro L.M., Sastre J., Rafael S.B., Vegazones S.B., Vidaurreta M., Martín M., Olivier C., de la Orden V.B., Garcia-Saenz J.A., Alfonso R., Arroyo M. and Diaz-Rubio E. (2009). Circulating tumor cells in solid tumor in metastatic and localizes stages. Anticancer Res. 29, 4839-4844.
27. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., Beitsch P., Khan A., Euhus D., Osborne C., Frenkel E., Hoover S., Leitch M., Clifford E., Vitetta E., Morrison L., Herlyn D., Terstappen L.W.M.M., Fleming T., Fehm T., Tucker T., Lane N., Wang J. and Uhr J. (2004). HER2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. USA 101, 9393-9398.
28. Meng S., Tripathy D., Shete S., Ashfaq R., Saboorian H., Haley B., Frenkel E., Euhus D., Leitch M., Osborne C., Clifford E., Perkins S., Beitsch P., Khan A., Morrison L., Herlyn D., Terstappen L.W.M.M., Lane N., Wang J. and Uhr J. (2006). uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc. Natl. Acad. Sci. USA 103, 17361-17365.
29. Mikolajczyk S.D., Millar L.S., Tsinberg P., Coutts S.M., Zomorrodi M., Pham T., Bischoff F.Z. and Pircher T.J. (2011). Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J. Oncol. 2011, 252361.
30. Molnar B., Ladanyi A., Tanko L., Sréter L. and Tulassay Z. (2001). Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin. Cancer Res. 7, 4080-4085.
31. Morishita A., Gong J., Nomura T., Yoshida H., Izuishi K., Suzuki Y., Kushida Y., Haba R., D'Armiento J. and Masaki T. (2010). The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. Int. J. Oncol. 37, 829-835.
32. Müller V., Hayes D.F. and Pantel K. (2006). Recent translational research: circulating tumor cells in breast cancer patients. Breast Cancer Res. 8, 110.
33. Nathanson D.R., Culliford IV A.T., Shia J., Chen B., D'Alessio M., Zeng Z-S., Nash G.M., Gerald W., Barany F. and Paty P.B. (2003). HER 2/neu expression and gene amplification in colon cancer. Int. J. Cancer 105, 796-802.
34. Pantel K. and Brakenhoff R.H. (2004). Dissecting the metastatic cascade. Nat. Rev. Cancer 4, 448-456.
35. Paterlini-Brechot P. and Benali N.L. (2007). Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 253, 180-204.
36. Pierga J.Y., Bidard F.C., Mathiot C., Brain E., Delaloge S., Giachetti S., de Cremoux P., Salmon R., Vicent-Salomon A. and Marty M. (2008). Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin. Cancer Res. 14, 7004-7010.
37. Sastre J., Maestro M.L., Puente J., Veganzones S., Alfonso R., Rafael S., García-Saenz J.A., Vidaurreta M., Martín M., Arroyo M., Sanz-Casla M.T. and Díaz-Rubio E. (2008). Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann. Oncol. 19, 935-938.
38. Slamon D., Leyland-Jones B., Hak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J. and Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
39. Swennenhuis J.F., Tibbe A.G.J., Levink R., Sipkema R.C.J. and Terstappen L.W.M.M. (2009). Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A 75, 520-527.
40. Takenaka M., Hanagiri T., Shinohara S., Kuwata T., Chikaishi Y., Oka S., Shigematsu Y., Nagata Y., Shimokawa H., Nakagawa M., Uramoto H., So T. and Tanaka F. (2011). The prognostic significance of HER2 overexpression in non-small cell lung cancer. Anticancer Res. 31, 4631-4636.
41. Thorsteinsson M., Söletormos G. and Jess P. (2011). Low number of detectable circulating tumor cells in non-metastatic colon cancer. Anticancer Res. 31, 613-618.
42. Tsapralis D., Panayiotides I., Peros G., Liakakos T. and Karamitopoulou E. (2012). Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J. Gastroenterol. 18, 150-155.
43. Weber-Matthiesen K., Winkemann M., Müller-Hermelink A., Schlegelberg B. and Grote W. (1992). Simultaneous fluorescence immunophenotyping and interphase cytogenetics: A contribution to the characterization of tumor cells. J. Histochem. Cytochem. 40, 171-5.
44. Wind J., Tuynman J.B., Tibbe A.G.J., Swennenhuis J.F., Richel D.J., van Berge Henegouwen M.I. and Bemelman W.A. (2009). Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. Eur. J. Surg. Oncol. 35, 942-950.
45. Wülfing P., Borchard J., Buerger H., Heidl S., Zänker K.S., Kiesel L. and Brandt B. (2006). HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 12, 1715-1720.